0.233
0.00 (1.39%)
| Penutupan Terdahulu | 0.230 |
| Buka | 0.230 |
| Jumlah Dagangan | 2,952,871 |
| Purata Dagangan (3B) | 3,674,037 |
| Modal Pasaran | 28,185,310 |
| Harga / Jualan (P/S) | 53.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 15 May 2026 |
| EPS Cair (TTM) | 4.09 |
| Nisbah Semasa (MRQ) | 0.720 |
| Aliran Tunai Operasi (OCF TTM) | -64.05 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -35.91 M |
| Pulangan Atas Aset (ROA TTM) | -122.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Outlook Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.88 |
|
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 38.31% |
| % Dimiliki oleh Institusi | 16.89% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gilpin Wealth Management, Llc | 31 Mar 2026 | 600,162 |
| Warberg Asset Management Llc | 31 Mar 2026 | 275,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 6.00 (Ascendiant Capital, 2,472.90%) | Beli |
| Median | 1.00 (328.82%) | |
| Rendah | 0.500 (HC Wainwright & Co., 114.41%) | Pegang |
| Purata | 2.50 (972.04%) | |
| Jumlah | 1 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 0.418 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Ascendiant Capital | 11 Mar 2026 | 6.00 (2,472.90%) | Beli | 0.434 |
| Chardan Capital | 18 Feb 2026 | 1.00 (328.82%) | Pegang | 0.410 |
| HC Wainwright & Co. | 18 Feb 2026 | 0.500 (114.41%) | Pegang | 0.410 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |